CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 39 enrolled
Drug / intervention
Dexmedetomidine +2 moredrug
Likely dose
Dexmedetomidine 0.5 mcg/kg bolus over 1 minute followed by 0.15 mcg/kg/hr infusion, with propofol 2.0 mg/kg bolus over 1 minute then 0.5 mg/kg bolus q 1 minute (Group DP) or propofol alone with same regimen (Group P)AI-extracted
Key inclusion· 2
  • Age 7–18 years scheduled for upper or lower endoscopic procedures at Boston Children's Hospital and meeting sedation criteria
  • Negative pregnancy test for females of childbearing age
Key exclusion· 13
  • History of allergy, intolerance, or reaction to dexmedetomidine or propofol or hypersensitivity
  • Current, repaired, or risk of Moya-Moya disease
  • Recent stroke (cerebrovascular accident) within past 6 months
  • Uncontrolled hypertension

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02952222
NCT02952222Phase 4Completed

The Synergistic Effect of Dexmedetomidine on Propofol for Sedation for Pediatric Endoscopy

Keira Mason·interventional·Posted Nov 2, 2016·Updated May 10, 2024

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine, Propofol (Group P), and 1 other intervention for Anesthesia. Completed, enrolled 39 participants across 1 site.

Detailed Summary

The primary aim of this study is to compare the propofol requirements of children who receive propofol with that of children who receive dexmedetomidine prior to propofol, for sedation for upper and lower endoscopic procedures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2, 2016
Enrollment StartMay 11, 2018
Primary CompletionSep 11, 2019
Study CompletionSep 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.7 years ago

Interventions

Dexmedetomidinedrug

Patients in Group DP will receive 0.5 mcg/kg Dexmedetomidine (DEX) administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of Bispectral Index (BIS) 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.

Propofol (Group P)drug

Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.

Propofol (Group DP)drug

Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.